體外診斷(IVD)的全球市場:趨勢與市場最新資訊:2025年

In Vitro Diagnostic (IVD) Trends and Market Update, 2025

出版日期: 2025年04月08日 | 出版商:

Kalorama Information | 英文 50 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

本報告提供了在持續的經濟和全球不確定性背景下動態體外診斷（IVD）市場的最新見解。

2024 年，IVD 市場將繼續擴大，儘管 COVID-19 檢測收入有所下降，但大多數細分市場仍將實現成長。人工智慧驅動的創新、監管變化和全球醫療保健支出的變化正在塑造競爭格局，並使 IVD 行業更具彈性。

產業重點關注且有望在未來 IVD 領域發揮關鍵作用的關鍵成長領域包括：

照護現場糖尿病檢驗
伴隨式診斷技術
免疫化學
質譜分析

核酸化驗
遺傳基因檢驗
HPV分子診斷

本報告提供全球體外診斷(IVD)市場相關調查，彙整推動市場要素主要的與產業趨勢，IVD革新形成的新產品開發，競爭情形的考察主要企業趨勢，新的成長機會及策略性成長領域等資料。

Kalorama Information's "In Vitro Diagnostic (IVD) Trends and Market Update, 2025" provides the latest insights into the dynamic IVD market amid ongoing economic and global uncertainties. Published twice a year-first in April 2025 and again in Q4 2025, following the release of Kalorama's annual 1,600-page study, "The Worldwide Market for In Vitro Diagnostics (IVD), 18th Edition"-this report serves both as a standalone resource and a companion to Kalorama's annual flagship IVD analysis.

In 2024, the IVD market continued to expand, with most segments experiencing growth, despite the decline in COVID-19 testing revenues. AI-driven innovations, regulatory shifts, and changes in global healthcare spending are shaping the competitive landscape, reinforcing the resilience of the IVD sector.

Key growth areas attracting industry attention and that are anticipated to play a significant role in the future of IVD include:

Point-of-care diabetes testing
Companion diagnostics technologies
Immunochemistry
Mass spectrometry

Nucleic acid assays
Gene testing
HPV molecular diagnostics

This report delivers timely and actionable intelligence, covering:

Market drivers and major industry trends
New product developments shaping IVD innovation
Competitive landscape insights and activities of key players
Emerging opportunities and strategic growth areas

With a commitment to delivering precise and up-to-date market intelligence, Kalorama Information continues to provide industry stakeholders with critical data and expert analysis to navigate the ever-evolving IVD landscape.

Chapter 1: Worldwide IVD Market Update - April 2025

IVD Market Demand and Growth
- Figure 1-1: Segment Performance Commentary, Q1-Q4 2024
- Table 1-1: Global In Vitro Diagnostic Sales, by Product Market, 2024 ($ million) [Blood bank molecular - NAT Screens, Blood grouping/typing, Circulating tumor cells, Clinical Chemistry, Coagulation (PT/INR), Coagulation, molecular, D-dimer, Hematology - Core Lab, Histology/cytology, HPV, molecular, Immunoassays - non-isotopic (Immuno - Infectious disease, Other immune, Immuno - Blood bank screening, Drugs of Abuse, Diabetes HbA1c, lab), Mass Spectrometry, Microbiology (ID/AST), Microbiology (molecular), Microbiology - Mass Spectrometry, Nucleic acid assays/genetic tests, Other (transplant testing, other, etc.), POC, OTC diabetes, POC, OTC other, POC, professional/hospital]
- Figure 1-2: Quarterly IVD Segment Performance, by Segment, Q1 2024 - Q4 2024 ($ million) [Clinical Chemistry, Coagulation, Hematology, Histology, Immunoassay, Microbiology, POC, Other]
- Figure 1-3: IVD Segment Performance, Total Market Value, 2024 ($ million) [Clinical Chemistry, Coagulation, Hematology, Histology, Immunoassay, Microbiology, POC, Other]
COVID-19 Diagnostic Markets
- Table 1-2: COVID-19 Product Sales, 2024 ($ million) [Immunoassay (Antigen, Serology), Molecular, Rapid]
Effect of COVID-19 on Market Segments
- Table 1-3: IVD Market Excluding and with COVID-19, 2024 ($ million)
- Figure 1-4: IVD Market Distribution, by Segment, 2024 (%) [IVD Market Excluding COVID-19 Assays and Instruments, COVID-19 Assays and Instruments]
- Figure 1-5: IVD Market by COVID-19 and non-COVID Markets, Quarterly Performance, 2024 ($ million) [IVD Market Excluding COVID-19 Assays and Instruments, COVID-19 Assays and Instruments]
- Table 1-4: Global In Vitro Diagnostic Market, YoY Growth 2023-2024 (%) [Blood bank molecular - NAT Screens, Blood grouping/typing, Circulating tumor cells, Clinical Chemistry, Coagulation (PT/INR), Coagulation, molecular, D-dimer, Hematology - Core Lab, Histology/cytology, HPV, molecular, Immunoassays - non-isotopic (Immuno - Infectious disease, Other immune, Immuno - Blood bank screening, Drugs of Abuse, Diabetes HbA1c, lab), Mass Spectrometry, Microbiology (ID/AST), Microbiology (molecular), Microbiology - Mass Spectrometry, Nucleic acid assays/genetic tests, Other (transplant testing, other, etc.), POC, OTC diabetes, POC, OTC other, POC, professional/hospital]
- Figure 1-6: Global In Vitro Diagnostic Market - YoY Growth 2023-2024 (%) [Blood bank molecular - NAT Screens, Blood grouping/typing, Circulating tumor cells, Clinical Chemistry, Coagulation (PT/INR), Coagulation, molecular, D-dimer, Hematology - Core Lab, Histology/cytology, HPV, molecular, Immunoassays - non-isotopic (Immuno - Infectious disease, Other immune, Immuno - Blood bank screening, Drugs of Abuse, Diabetes HbA1c, lab), Mass Spectrometry, Microbiology (ID/AST), Microbiology (molecular), Microbiology - Mass Spectrometry, Nucleic acid assays/genetic tests, Other (transplant testing, other, etc.), POC, OTC diabetes, POC, OTC other, POC, professional/hospital]

Chapter 2: Product Trends and New Developments

Liquid Biopsy
Mass Spectrometry
Immunoassay
Molecular
Personalized Medicine
POC
Sequencing
Antigen/Antibody
Molecular

Chapter 3: Top IVD Market Participant Results

Selected Competitive Leader Updates
- Figure 3-1: IVD Segment Growth by Leading Competitors, Change in Sales 2023-2024 (%) [Abbott Diagnostics, Becton Dickinson, bioMerieux, Danaher, Dexcom, QuidelOrtho, Roche Diagnostics, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific]
- Figure 3-2: IVD Sales Changes in Market Distribution, 2021-2024 - Roche and Abbott Battle for #1 Spot (%) [Abbott Diagnostics, Becton Dickinson, bioMerieux, Danaher, Dexcom, Exact Sciences, Hologic, QuidelOrtho, Roche Diagnostics, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific, Werfen, Others]
- Figure 3-3: Comparison of Total Diagnostic Sales for Abbott vs Roche, 2022-2024 ($ million)
Q4 2024, Q1 2025 M&A Activity
- Table 3-1: Q4 2024, Q1 2025 Merger and Acquisition Activity
Abbott Laboratories
- Table 3-2: Abbott Corporate Summary
Becton Dickinson and Co
- Table 3-3: Becton Dickinson Corporate Summary
bioMerieux SA
- Table 3-4: bioMerieux Corporate Summary
Danaher Corporation
- Table 3-5: Danaher Corporation Summary
Dexcom, Inc
- Table 3-6: Dexcom Corporate Summary
Exact Sciences
- Table 3-7: Exact Sciences Corporate Summary
QuidelOrtho Corporation
- Table 3-8: QuidelOrtho Corporate Summary
Roche Diagnostic
- Table 3-9: Roche Diagnostic Corporate Summary
Siemens Healthineers
- Table 3-10: Siemens Healthineers Corporate Summary
Sysmex Corporation
- Table 3-11: Sysmex Corporate Summary
Thermo Fisher Scientific
- Table 3-12: Thermo Fisher Scientific Corporate Summary